Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma
NCT05627115
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
80
Enrollment
OTHER
Sponsor class
Conditions
Hodgkin Lymphoma
Interventions
DRUG:
Tislelizumab, AVD, Radiotherapy
Sponsor
University College, London
Collaborators
[object Object]